Immunology

Harnessing human-first models to accelerate drug discovery, improve safety, and capture the diversity of human biology.

Trinity College Dublin researchers report a nasal vaccine that prevented infection and spread of pertussis in preclinical models.

Acquisition brings Avidity’s RNA delivery platform and late-stage neuromuscular programs under Novartis, expanding its capabilities in developing precision genetic medicines.

ImmunoVec will use a $40.7 million grant to advance its polymeric nanoparticle platform toward a first-in-human trial for autoimmune diseases.

New study identifies fibroblast subtypes as potential universal drug targets in cancer, skin, and inflammatory diseases.

Nearly 25 percent of non-antibiotic drugs tested in the study enabled the proliferation of enteropathogens.

Scientists are advancing CAR T cell therapy to improve outcomes for children with acute lymphoblastic leukemia.

Papzimeos is the first FDA-approved therapy for recurrent respiratory papillomatosis, a rare HPV-driven disease that has long forced patients into repeated surgeries.

Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.

Discover how coculture models and CRISPR tools reveal new insights into tumour microenvironments.

Macrophage-based therapies for liver cirrhosis are entering clinical trials, but key challenges remain before they become a viable treatment.

Explore how combining human immune and epithelial or cancer cells in vitro enhances predictive power in infectious disease and oncology research.